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Abstract
Background: Melanoma and renal cell carcinoma (RCC) are traditionally considered less radioresponsive than other
histologies. Whereas stereotactic body radiation therapy (SBRT) involves radiation dose intensification via escalation,
we hypothesize SBRT might result in similar high local control rates as previously published on metastases of
varying histologies.
Methods: The records of patients with metastatic melanoma (n = 17 patients, 28 lesions) or RCC (n = 13 patients,
25 lesions) treated with SBRT were reviewed. Local control (LC) was defined pathologically by negative biopsy or
radiographically by lack of tumor enlargement on CT or stable/declining standardized uptake value (SUV) on PET
scan. The SBRT dose regimen was converted to the single fraction equivalent dose (SFED) to characterize the dose-
control relationship using a logistic tumor control probability (TCP) model. Additionally, the kinetics of decline in
maximum SUV (SUVmax) were analyzed.
Results: The SBRT regimen was 40-50 Gy/5 fractions (n = 23) or 42-60 Gy/3 fractions (n = 30) delivered to lung (n
= 39), liver (n = 11) and bone (n = 3) metastases. Median follow-up for patients alive at the time of analysis was
28.0 months (range, 4-68). The actuarial LC was 88% at 18 months. On univariate analysis, higher dose per fraction
(p < 0.01) and higher SFED (p = 0.06) were correlated with better LC, as was the biologic effective dose (BED, p <
0.05). The actuarial rate of LC at 24 months was 100% for SFED ≥45 Gy v 54% for SFED <45 Gy. TCP modeling
indicated that to achieve ≥90% 2 yr LC in a 3 fraction regimen, a prescription dose of at least 48 Gy is required. In
9 patients followed with PET scans, the mean pre-SBRT SUVmax was 7.9 and declined with an estimated half-life of
3.8 months to a post-treatment plateau of approximately 3.
Conclusions: An aggressive SBRT regimen with SFED ≥ 45 Gy is effective for controlling metastatic melanoma and
RCC. The SFED metric appeared to be as robust as the BED in characterizing dose-response, though additional
studies are needed. The LC rates achieved are comparable to those obtained with SBRT for other histologies,
suggesting a dominant mechanism of in vivo tumor ablation that overrides intrinsic differences in cellular
radiosensitivity between histologic subtypes.
Background
For at least three decades, renal cell carcinoma (RCC)
and melanoma have been considered to be relatively
“radioresistant” tumors. In the case of RCC, this opinion
was initially based on observations that substantially
higher doses of conventionally fractionated radiotherapy
(RT) must be employed to achieve the same level of
clinical response produced with lower dose for most
other histologies [1]. For the case of melanoma, labora-
tory studies in the early 1970s suggested that higher
radiation doses per fraction would be needed to achieve
effective cell kill [2]. Subsequently, clinical investigations
of hypofractionated RT were initiated to evaluate this
approach to enhance radiation cytotoxicity [3].
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support the prevailing pessimistic viewpoints about RCC
and melanoma response to RT. A dose-response rela-
tionship for palliative effect was observed by Onufrey
and Mohiuddin among 125 patients treated for meta-
static RCC [4], though their results were somewhat at
variance with those of Halperin and Harisidias [5]. Mul-
tiple melanoma randomized studies were performed
both in Europe and in the United States to explore ways
to refine the use of RT in that setting: a Danish study
found equivalence between 27 Gy in 3 fractions and 40
Gy in 5 fractions, and an RTOG study likewise found
equivalence between 50 Gy in 20 fractions and 32 Gy in
4 fractions in terms of response rate [6,7].
More recently, high single doses of radiation delivered
during stereotactic radiosurgery (SRS) to brain and
spinal metastases have been studied in both melanoma
and RCC, with encouraging outcomes [8-13]. Pre-clini-
cal evidence has likewise indicated that a multi-session,
high dose per fraction regimen of the type commonly
used for stereotactic body radiation therapy (SBRT) is
effective in the treatment of RCC [14], an observation
further supported by clinical observations [15,16]. To
our knowledge identical pre-clinical studies have not
been reported for melanoma.
The increasingly popular use of high dose per frac-
tion, SBRT-type regimens for not only melanoma and
RCC but also for a variety of other lesions [17,18] has
prompted a re-analysis of the traditional linear-quadra-
tic (LQ) model-based formalism for predicting the
radiation dose-response relationship for SBRT, since
there is reason to consider that the LQ model overesti-
mates radiation-induced cytotoxicity at high dose per
fraction [19]. To begin to understand the potential
benefits of SBRT for these histologies, we undertook a
review of our institutional experience at the University
of Colorado involving the use of SBRT for RCC and
melanoma.
The first objective was to analyze whether the local
control rates reported for high dose per fraction cra-
nial and spinal SRS for RCC and melanoma can be
replicated in other sites. Second, we attempted to
model the SBRT dose-response relationship. In this
context, we used both a traditional linear-quadratic
model-based metric, the biological equivalent dose
(BED), and a novel index proposed for modeling high
dose per fraction RT, the single fraction equivalent
dose (SFED)[19]. Finally, we reviewed the clinical
observations typically seen in terms of metabolic ima-
ging following SBRT for RCC and melanoma and the
overall survival of this population of patients, with the
intent of offering guidance for proper patient
selection.
Methods
We retrospectively reviewed all patients with melanoma
and RCC treated with SBRT to metastatic sites from
October 2004 to November 2009 at the University of
Colorado. This study was approved by the University of
Colorado Institutional Review Board. All patient charts
were reviewed for clinical information including treat-
ments with systemic therapies. Patients were excluded
for review if they did not have any follow-up imaging
after SBRT. Patients were considered to have oligometa-
static disease if they had three or fewer sites of metas-
tases in which all sites were treated with aggressive local
therapy with possible systemic therapy. Otherwise,
patients were classified as having extensive metastatic
disease. Patients with extensive disease had relatively
stable systemic disease with either painful lesions or
growing lesions which were treated with SBRT.
SBRT was defined as a minimum total dose of 40 Gy
given in 5 or fewer fractions using stereotactic technique
previously described [20]. Briefly, for treatment plan-
ning, the gross tumor volume (GTV) was considered
equal to the clinical target volume (CTV). The planning
target volume (PTV) was typically constructed by adding
5 mm radially and 5-10 mm in the superior-inferior
direction. The dose was prescribed to cover at least 95%
of the PTV, normalized to the isodose line representing
60-80% of the maximum dose inside the PTV. The
majority of plans were generated using multiple dynamic
conformal arcs with at least 1 non-coplanar arc or a
combination of multiple static beams. Localization was
performed with KV orthogonal imaging fused to plan-
ning CT with the isocenter re-marked after shifts.
Patients then underwent CT simulation for verification
that the newly marked isocenter was within the GTV. In
recent years, after the acquisition of 4D CT simulation
technology, when significant breathing-related motion
was present, the PTV was constructed by enlarging the
internal target volume (ITV) defined on a 4D imaging
set by 5 mm in all directions. Patients underwent
abdominal compression to limit respiratory motion.
Toxicity was scored according to the Common Termi-
nology Criteria for Adverse Events v3.0. The use of
RECIST (Response Evaluation Criteria in Solid Tumors)
criteria after SBRT is difficult in view of the expected par-
enchymal changes commonly seen in surrounding normal
tissue within the volume that receives approximately 20
Gy or higher. For this reason, we did not characterize
lesions as having had a complete response or partial
response by RECIST criteria. Instead, local failure was
scored when one of the following conditions were met: (1)
tumor viability as seen by an increase in SUV on follow-
up PET scan relative to the most recent prior PET; (2)
expansion of a solid mass with discrete borders within the
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most recent prior CT or MRI; or (3) tumor viability as evi-
denced pathologically by biopsy. In questionable cases, the
follow-up CT was fused with the planning CT to define
in-field LC. If a patient with suspicious failure was subse-
quently treated for that lesion with chemotherapy, the
lesion was considered a failure. Overall survival (OS) was
recorded from the date of treatment completion to last
follow-up or date of death.
The SBRT dose regimen used was then converted to
single fraction equivalent dose (SFED) using the follow-
ing equation:
SFED = D − (n − 1) × Dq
with Dq estimated at 1.8 from the Park analysis [19].
Local control curves were generated using Kaplan-Meier
method. Comparisons between curves were performed
using the log rank method. Candidate predictors for
local control (total dose, GTV, histology etc) were also
evaluated by log rank analysis. Univariate analysis was
performed with the median value using log rank com-
parisons (GraphPad Prism
®, GraphPad Software, Inc., La
Jolla California).
The dose-response relationship was modeled using a
logistic tumor control probability (TCP) formula [21]:
TCP =
1
(1+(TCD50/D)k)
W h e r eDi st h et o t a ld o s e ,T C D 50 i st h ed o s et h a t
achieves 50% tumor control, and k describes the slope of
the curve. Doses to individual lesions were grouped into
tertile bins, and the x-axis value was the mean dose given
in that bin, expressed as either BED or SFED, while the
y-axis value was the probability of LC at twelve months.
In patients undergoing surveillance with PET scans
who had long term local control, we looked at the pattern
of the maximal standardized uptake value (SUV) change.
Only patients with a pre-treatment and at least one post-
treatment PET scan were included for analysis. The PET
scans were performed intermittently for tumor surveil-
lance and regularly in patients undergoing chemotherapy
for other sites of disease. The lesions were contoured
using dedicated medical image analysis software (MIM-
vista
®, MIM Software, Inc., Cleveland, Ohio). This was
then fused to their follow up PET scans and the maxi-
mum SUV (SUVmax) was calculated for each lesion on
each PET scan performed. Nine patients with 12 lesions
had a total of 43 PET scans prior to and after SBRT.
Results
Patient population
Thirty patients with 53 treated lesions met the study
inclusion criteria and were analyzed. Overall, 17
melanoma patients had 28 lesions, and 13 RCC patients
had 25 lesions available for review. Two patients with
RCC did not have follow-up imaging and were not
included, one melanoma patient had an additional lesion
that was treated but did not have any follow-up imaging
and this lesion was excluded from our analysis. Patient
ages ranged from 36 to 83, with median age of 59.
There were 17 males and 13 females treated with SBRT.
Seventeen patients had oligometastatic disease at time of
treatment with all sites treated with SBRT, and 13
patients had extensive disease in which only selected
lesions were treated with SBRT. The median number of
lesions treated per patient was 2 (range, 1-3). Among
the tumor sited treated, lung was most common (n =
39), followed by liver (n = 11) and bone (n = 3).
The SBRT regimens were 40-50 Gy delivered in 5
fractions (n = 23) or 42-60 Gy delivered in 3 fractions
(n = 30). The regimen applied was selected at the dis-
cretion of the treating physician in view of clinical
objectives and normal tissue dose considerations for
each lesion without regard to the histology. The aim
was to safely deliver the highest dose possible while
respecting the surrounding normal tissue tolerance. The
most common regimen was 60 Gy in 3 fractions (n =
20) followed by 45 Gy in 5 fractions (n = 11) and 50 Gy
in 5 fractions (n = 8). Median gross tumor volume
(GTV) was 6.3cc (range, 1-275). Median follow-up for
patients alive at the time of analysis was 28.0 months
( r a n g e ,4 - 6 8 ) .S e et a b l e1f o r treatment characteristics
including SFED and BED values for each regimen.
Tolerance and other therapies
There were no acute side effects, only mild late toxici-
ties which were not dose dependent. Six patients experi-
enced grade 1 toxicity (3 pain, 2 cough and 1 dyspnea).
There was one incident of grade 3 toxicity of hypoxia at
11 months after treatment in an asthmatic patient who
developed multiple pulmonary metastases requiring
increased continuous oxygen use. One patient developed
grade 3 radiation pneumonitis successfully managed
with steroids.
Table 1 Treatment Characteristics
Fractionation Schedule # of pts SFED (Gy) BED (Gy)
60 Gy in 3 fractions 20 56.4 180
54 Gy in 3 3 50.4 151.2
50 Gy in 5 8 42.8 100
45 Gy in 3 5 41.4 112.5
42 Gy in 3 2 38.4 100.8
45 Gy in 5 11 37.8 85.5
40 Gy in 5 4 32.8 72
Fractionation schedules and conversion to single fraction equivalent dose
(SFED) and biological equivalent dose (BED).
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SBRT and 2 after SBRT as well as 7 patients treated
with sunitinib. One patient underwent SBRT while suni-
tinib was held for 2 weeks before and after treatment, 3
patients were treated with sunitinib before SBRT and 3
patients were treated after SBRT. There was no signifi-
cant increase in toxicity seen in these 14 patients (two
grade 1 events and one late grade 3 pneumonitis). One
patient with melanoma received CTLA4 antibody after
radiation and did not experience any adverse side effects
from SBRT. Overall patients were pre-treated with a
variety of systemic therapies. The median number of
courses was 1 with range 0-3. Additionally, patients
went on to further systemic therapy with a median of
one course (range 0-5).
Local control and overall survival
The actuarial rate of LC for all patients was 88% at 18
months (Figure 1). Several factors were analyzed by uni-
variate analysis in an effort to identify predictors of LC. In
general, for quantitative parameters, the median value was
chosen as an arbitrary cut-off for univariate analysis to
maximize the comparison cohorts. Log rank comparison
revealed number of fractions (3 vs 5, p < 0.01) as well as
dose per fraction (> 11 Gy/fraction vs <11 Gy/fractions, p
< 0.01) and BED ( > 100 Gy vs < 100 Gy, p < 0.01) to be
significant predictors of LC. Histology (RCC vs melanoma,
p = 0.06) total dose (≥50Gy vs <50Gy, p = 0.09) SFED (≥
45 Gy vs < 45 Gy, p = 0.06) and GTV (>7cc vs <7cc, p =
0.06) showed a strong trend towards significance. Site trea-
ted (lung vs other) and disease burden (oligometastatic vs
widely metastatic) were not predictors of local control.
Given the small number of events available to analyze, a
multivariate analysis was not performed.
We generated TCP graphs using both SFED and BED
(Figure 2). Both SFED and BED had a strong coefficient
of determination to predict future outcomes (SFED R =
0.999 and BED R = 0.996). Using the SFED TCP graph,
a 90% chance of tumor control was calculated to an
SFED of 44.3 Gy which translates into approximately 48
Gy in 3 fractions. Using BED, 90% chance of tumor con-
trol was calculated at 126 Gy, which corresponds to
approximately 49 Gy in 3 fraction regimen.
M e d i a no v e r a l ls u r v i v a lf o ra l lp a t i e n t si nt h i ss t u d y
was 24.3 months. The median overall survival of
patients with oligometastatic disease was not reached
while patients with extensive metastatic disease had a
median overall survival of only 12.3 months (p = 0.03)
(Figure 3). Median overall survival was not reached in
patients with RCC, and was statistically longer than mel-
anoma patients with median overall survival of 22.2
months (p = 0.015).
Metabolic imaging and kinetics of PET scan changes
The SUVmax was plotted and fitted with an exponential
equation. The median pre-treatment SUVmax was 7.9
(range 1.5 - 14.6). The calculated time for the SUVmax
v a l u et od e c r e a s eb yh a l ft h eo r i g i n a lv a l u ew a s3 . 8
months (Figure 4). We found that the calculated post-
treatment baseline SUVmax was 2.6, which was reached
at approximately 7 months. The median post-treatment
SUVmax was 2.5 (range 1.8 - 3.2).
Discussion
We have observed in a cohort of patients treated with
SBRT for metastatic melanoma or RCC, a high rate of
durable LC can be achieved, especially for patients with
a 3 fraction SBRT total prescription dose on the order
of 48-49 Gy or higher. It should be appreciated that this
dose estimate represents the dose covering the periphery
of the PTV and that substantial dose hotspots are always
created in the GTV. Thus, the actual dose need to
ablate the gross disease itself is higher than this
estimate.
T h ed a t aw e r ee v a l u a t e di nt e r m so fS F E Da n dB E D
because these indices incorporate both the total dose
d e l i v e r e da sw e l la st h ed o s ep e rf r a c t i o n .S F E Dw a s
designed to analyze the effect of high dose per fraction
exposure by using an equation for cell survival which,
when plotted a logarithmic scale, initially curves down-
ward with increasing dose in a similar way as an LQ-
based curve but then straightens at higher doses, cor-
recting for an overestimation of cell kill by BED in the
S B R T / a b l a t i v ed o s er a n g e[ 2 2 ] .T h e r ea r ea tl e a s tt w o
reasons why the BED might not characterize high dose
effects as well as a model such as the SFED. First of all,
there is the phenomenon recognized long ago whereby
for lengthy individual exposures of living cells to
Figure 1 Local Control. Actuarial local control for both melanoma
and RCC lesions
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correction to the simple LQ model that adjusts for this
process. This notion was advanced at least as long ago
as the 1940s, when Lea and Catcheside modeled radia-
tion-induced chromosomal aberrations in a plant model
using a linear-quadratic formula that also could be mod-
ified with a factor that accounted for the total time of
exposure [23].
A second, more modern explanation of why BED
might not precisely model high dose effects relates to a
mechanism of tumor cell kill at work in vivo that is not
active in vitro. With conventionally fractionated doses,
radiation cell kill is assumed to be largely mediated
through oxygen dependent DNA damage with resulting
loss of clonogenicity, an effect seen in vitro and pre-
sumed to occur in vivo. However, pre-clinical studies
have suggested that the high doses of radiation delivered
in each session of SBRT might trigger an entirely differ-
ent method of cell kill in vivo via an anti-angiogenic
pathway involving endothelial cell apoptosis [24]. Coin-
cidentally, apropos of the present clinical series, the pre-
clinical studies initially suggesting this mechanism
included studies of melanoma xenografts. Furthermore,
endothelial cell apoptosis appeared to be induced above
a threshold dose of 11 Gy, and the present study simi-
larly suggested significant improvement in tumor cell
Figure 2 Tumor Control Probability. Tumor Control Probability graphs generated from dose response relationship modeling. Doses to
individual lesions were grouped into tertile bins and the x-axis value was the mean dose given in that bin, expressed as either (a) SFED or (b)
BED. The y-axis value was the probability of LC at 12 months.
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anoma and RCC have also been shown to have a large
initial shoulder on the cell survival curve [25], and the
present study’s favorable results might also be at least
partly explained by the fact that doses in the SBRT
range exceed that of the initial shoulder region. Both
BED and SFED proved to be a reliable predictor for LC.
Further studies will be needed to resolve whether one is
truly superior to the other, and it will be informative to
see the results of RTOG 0915 in which a single 34 Gy
fraction is compared to 48 Gy in 4 fraction regimen for
primary lung cancer. The SFED model would predict
better LC with the 48 Gy arm, while BED modeling pre-
dicts the single 34 Gy treatment to have superior LC.
The present clinical observations of high LC after
aggressive radiation treatment are consistent with what
has been observed after single high dose SRS to brain
and spinal metastases for both melanoma and RCC
[8-10,26]. In these studies the LC for melanoma is typi-
cally lower than for RCC [10,26], for which brain SRS
can achieve very high LC [11]. Likewise, in the present
study we observed a trend for lower 1 year LC for mela-
noma than RCC (82% v. 95%), possibly intrinsic differ-
ences in radiosensitivity that are retained even in the
high dose-per-fraction setting. In a study of SBRT in
primary and metastatic RCC, the local control rate was
90-98% [16] which is in line with our own and other
institutional local control rates across a broad range of
histologic subtypes [16-18,27,28].
The oligometastatic hypothesis suggests that tumors
early in systemic disease progression may present with a
limited number of discrete lesions without extensive
occult spread of disease, thus a condition amenable to
potentially curative intervention if the identifiable
lesions can be eradicated [29]. Studies of liver metaste-
ctomy in patients with RCC reveal that there are long
term survivors and chance for cure with a 5 year OS
rate of 39% [30]. The argument for using ablative local
therapy for isolated metastases is strengthened if effec-
tive systemic therapy is available to complement it [31].
And in recent years, for both melanoma and RCC there
have been new systemic agents developed that provide
clinical benefit, including the anti-CTLA-4 antibody, ipi-
limumab, and multi-targeted agents such as sunitinib
and sorafenib.
Properly selected patients with metastatic RCC
undergoing lung resection have a chance for long term
survivorship [32], as do patients with liver metastases
from RCC, where a 5 year OS of approximately 40%
has been reported for a group of well selected patients
[30]. Patients with liver metastases from RCC tend to
fare better than patients with liver metastases from
melanoma [33], once again suggesting basic differences
in the typical degree of aggressiveness between these
cancer types. In the present series, melanoma patients
likewise had shorter median survival than RCC
patients.
In this series the arbitrary cutoff point applied to char-
acterize patients as having oligometastatic vs. extensive
metastatic disease was the presence of 3 or fewer indivi-
dual sites of disease. The superior outcome of patients
defined as oligometastatic by this definition was
expected, and this or a similar cutoff level of sites of dis-
ease would appear to be appropriate as a stratification
variable for future studies of SBRT in the treatment of
Figure 3 Overall survival. Actuarial overall survival of patients
based on disease state. Oligometastatic disease was defined as
three or less metastases in which all site of disease were treated
with aggressive local therapy. Extensive disease was defined as
patients with more than three sites of metastases.
Figure 4 Change in SUV for controlled lesions. The Standardized
uptake values were plotted with pre-treatment PET used for
planning as time 0. Follow-up PET/CT’s were fused and SUV was
generated for each treated lesion that was controlled. An
exponential equation was generated revealing a post-treatment
baseline level of activity of 2.6 at 7 months.
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between the cohorts defined in this manner does not
rule out the possibility that patients with more extensive
disease might still benefit from a general reduction in
their systemic disease burden, whether achieved by sys-
temic therapy or local therapy. Indeed, for the case of
RCC in particular, two independent phase III studies
indicate that a reduction in a patient’s total burden of
disease via nephrectomy lengthens OS for patients with
known metastatic disease, even though not all sites of
disease were locally treated [34]. Thus, as studies are
designed in the future, it is important to avoid the
overly narrow assumption that only patients with oligo-
metastatic disease can potentially benefit from ablation
of metastatic sites of disease via local therapy, though
certainly patients with more limited disease will have a
better prognosis overall.
PET scans are now widely available to monitor
response to cancer therapy in a variety of setting, and
we have here reported on the kinetics of change in
metabolic activity following SBRT for RCC and mela-
noma. In our cohort of locally controlled patients, the
decrease to a steady post-treatment baseline SUVmax
took approximately 7 months. The post-treatment
baseline level averaged 2.6 and was consistent with
findings of Henderson et al, who showed that almost
half of primary non-small cell lung cancer lesions have
moderately elevated SUVmax at 12 months without
local failure [35]. Hoopes also reviewed follow-up PET
scans in patients undergoing SBRT for NSCLC and
found that 14% of patients had moderate hypermeta-
bolic activity without local failure 20 months after
SBRT completion [36]. In addition to the baseline level
activity, we found the average time to decrease the
post-treatment SUVmax by half the value took 3.8
months. The residual activity observed after treatment
likely represents energy-dependent inflammatory and
tissue-reparative responses, but further analysis of the
nature of the lingering metabolic activity is beyond the
scope of the present study.
The present study results are the first to support inde-
pendently the observations of Wersall and colleagues
[16], who likewise saw longer survival in RCC patients
with oligometastatic disease compared with more exten-
sive disease. Furthermore, we here have analyzed data
using the recently proposed SFED metric, which at least
in this relatively small experience proved a robust pre-
dictor for LC. The present study likewise generates the
testable hypothesis that with adequately aggressive non-
invasive SBRT regimens incorporating high dose per
fraction schedules, the rates of LC achieved even for
classically “radioresistant” histologies appear similar to
what can be achieved for histologic subtypes expected
to be more radiosensitive.
Conclusions
The present study demonstrates that an aggressive
SBRT regimen is an effective modality for controlling
metastatic melanoma and RCC. The LC rates achieved
in our series are comparable to those obtained with
SBRT for other tumor histologies, suggesting a domi-
nant mechanism of in vivo tumor ablation after high
dose fractions that largely overrides intrinsic differences
in cellular radiosensitivity between histologic subtypes of
tumor. SFED TCP modeling indicates that to achieve a
high rate of durable LC in a 3 fraction regimen of
SBRT, a dose of at least 48 Gy is required.
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